UniProt Q8IWQ3 · PDB · AlphaFold · Substrate: ZIPtide · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 94.6% | 5.4% | 78.64 | 0.500 |
| 2 | Repotrectinib | 91.5% | 8.5% | 84.21 | 0.608 |
| 3 | Brigatinib | 77.8% | 22.2% | 82.96 | 0.513 |
| 4 | Axitinib | 76.0% | 24.0% | 93.23 | 0.688 |
| 5 | Rabusertib | 56.9% | 43.1% | 98.74 | 0.687 |
| 6 | Sunitinib | 43.6% | 56.4% | 91.73 | 0.524 |
| 7 | Defactinib | 31.9% | 68.1% | 92.68 | 0.450 |
| 8 | Dabrafenib | 23.8% | 76.2% | 94.74 | 0.633 |
| 9 | Selpercatinib | 22.3% | 77.7% | 96.72 | 0.635 |
| 10 | Abrocitinib | 21.3% | 78.7% | 99.50 | 0.581 |
| 11 | Crizotinib | 21.1% | 78.9% | 91.39 | 0.581 |
| 12 | Lorlatinib | 20.1% | 79.9% | 97.24 | 0.694 |
| 13 | Netarsudil | 17.1% | 82.9% | 93.22 | 0.676 |
| 14 | Dacomitinib | 16.7% | 83.3% | 97.99 | 0.664 |
| 15 | Paxalisib | 14.4% | 85.6% | 99.75 | 0.609 |
| 16 | Upadacitinib | 13.9% | 86.1% | 97.98 | 0.663 |
| 17 | Darovasertib | 13.8% | 86.2% | 96.99 | 0.719 |
| 18 | Mitapivat | 13.1% | 86.9% | 100.00 | 0.625 |
| 19 | Ceritinib | 13.0% | 87.0% | 95.44 | 0.618 |
| 20 | Baricitinib | 12.5% | 87.5% | 97.99 | 0.616 |
Paralog block
BRSK1, BRSK2
EMT expression
- Mesenchymal log2(TPM+1): 0.80
- Epithelial log2(TPM+1): 1.63
- Fold change: -0.83
- Status: No significant change
Selectivity landscape vs inhibition on BRSK2
Each point is one of the 92 approved drugs; color = inhibition % on BRSK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…